Plasma nucleic acids in the diagnosis and management of malignant disease

Clinical Chemistry

Volumn 48, Issue 8, 2002, Pages 1186-1193

  Johnson, Philip J ^a   Lo, Y M Dennis ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSATELLITE DNA; MITOCHONDRIAL DNA; MOLECULAR MARKER; NUCLEIC ACID; VIRUS DNA;

BLOOD LEVEL; BREAST CANCER; CHROMOSOME TRANSLOCATION; COLON CANCER; DISEASE ASSOCIATION; DNA METHYLATION; EPSTEIN BARR VIRUS; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NASOPHARYNX CARCINOMA; ONCOGENE; PROMOTER REGION; REVIEW;

HUMAN HERPESVIRUS 4;

EID: 0036320933     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.8.1186     Document Type: Review

References (77)

1. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology Expert Panel
2. 1997 Update recommendations of the use of tumor markers in breast and colorectal cancer
3. A framework for the molecular classification of circulating tumor markers
4. Free DNA in the serum of cancer patients and the effect of therapy
5. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease
6. Neoplastic characteristics of the DNA found in the plasma of cancer patients
7. Soluble normal and mutated DNA sequences from single-copy genes in human blood
8. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukemia
9. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer
10. A review of studies on the detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer
11. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer
12. Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis
13. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients
14. Somatic mutation screening: Identification of individuals harboring K-ras mutations with the use of plasma DNA
15. Serum mutant K-ras in the colorectal adenoma-to-carcinoma sequence. Implications for diagnosis, postoperative follow-up, and early detection of recurrent disease
16. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer
17. Utilization of K-ras mutations identified in stool DNA for the early detection of colorectal cancer
18. K-ras mutation: Early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers - A review
19. p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas
20. Detection of tumor mutant APC DNA in plasma of patients with sporadic colorectal cancer
21. Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients
22. Microsatellite alterations in serum DNA of head and neck cancer patients
23. Microsatellite alterations in plasma DNA of small cell lung cancer patients
24. Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer
25. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance
26. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients
27. Microsatellite alterations detected in the serum of early stage breast cancer patients
28. Detection of bladder cancer recurrence by microsateliite analysis of urine
29. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma
30. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer
31. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids
32. Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia
33. Serum BCL2/IGH DNA in follicular lymphoma patients: A minimal residual disease marker
34. Epigenetic lesions causing genetic lesions in human cancer: Promoter hypermethylation of DNA repair genes
35. Epigenetic tumor markers in plasma and serum: Biology and applications to molecular diagnosis and disease monitoring
36. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
37. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
38. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction
39. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
40. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients
41. DNA-based detection of prostate cancer in blood, urine, and ejaculates
42. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma
43. Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: Applications to tumor detection and monitoring
44. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma
45. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma
46. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma
47. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma
48. Quantitative and temporal correlation between circulating cell-free Epstein-Barr Virus DNA and tumor recurrence in nasopharyngeal carcinoma
49. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA
50. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease
51. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease
52. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease
53. Epidemiology of EBV and Hodgkin's lymphoma
54. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease
55. Detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction
56. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies
57. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma
58. Somatic mutations of the mitochondrial genome in human colorectal tumours
59. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids
60. Mitochondrial mutations in early stage prostate cancer and bodily fluids
61. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum
62. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma
63. Circulating hepatitis B virus nucleic acids in chronic infection: Representation of differently polyadenylated viral transcripts during progression to nonreplicative stages
64. Detection of tumor messenger RNA in the serum of patients with malignant melanoma
65. Detection of tumor-associated circulating mRNA in patients with disseminated malignant melanoma
66. Specific association of human telomerase activity with immortal cells and cancer
67. Telomerase RNA as a detection marker in the serum of breast cancer patients
68. Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: A simple blood test to monitor disease in cancer patients
69. Circulating RNA as a tumor marker: Detection of 5T4 mRNA in breast and lung cancer patient serum
70. Detection of mammaglobin mRNA in the plasma of breast cancer patients
71. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics
72. Detection of amplifiable messenger RNA in the serum of patients with lung cancer
73. Functionality of circulating DNA: The hypothesis of genometastasis
74. Automated assay for fetal DNA analysis in maternal serum
75. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation
76. Effects of blood processing protocols on fetal and total DNA quantification in maternal plasma
77. Circulating Fpstein-Barr virus DNA in the serum of patients with gastric carcinoma